Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi

• Published in: Immunotherapy Vol. 9; no. 7; pp. 555 - 565
• Main Authors: Bontempi, Ivan, Fleitas, Pedro, Poato, Alexia, Vicco, Miguel, Rodeles, Luz, Prochetto, Estefania, Cabrera, Gabriel, Beluzzo, Bruno, Arias, Diego, Racca, Andrea, Guerrero, Sergio, Marcipar, Iván
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-06-2017
• Subjects: Animals; Antigens; Chagas Disease - immunology; Clinical trials; Cruzipain; Cysteine Endopeptidases - immunology; Enzymes; Female; Freund's Adjuvant; Glycoproteins - immunology; Humans; Immune system; Immunity; Immunogenicity; Infections; Metabolic pathways; Mice; Mice, Inbred BALB C; Neuraminidase - immunology; Parasitemia; Parasites; Peroxidases - immunology; Proteins; Protozoa; Protozoan Proteins - immunology; Protozoan Vaccines - immunology; Survival; trans-Sialidase; Tropical diseases; Trypanosoma cruzi; Trypanosoma cruzi - immunology; Tryparedoxin peroxidase; Vaccination; Vaccines; Latin America; trans-sialidase; ISCOMATRIX; Trypanosoma cruzi
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt-2017-0009

The development of vaccines against Trypanosoma cruzi remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison among the performance of the immunogens cannot be carried out because the available reports differ in formulations and infection model. In this work, we compared the protective capacity of seven T. cruzi antigens in the same model of five new antigens and two well-established candidates. Materials & methods: We evaluated highly immunogenic proteins that contain tandem repeats (FRA [flagelar repetitive protein], Tc3, Tc6); enzymes involved in metabolic pathways critical for parasite survival (cytosolic tryparedoxin peroxidase and tryparedoxin peroxidase); and enzymes involved in parasite invasion (trans-sialidase [TS] and cruzipain). All these antigens were formulated with Freund's adjuvant and protection against the parasite infection was assessed in BALB/c mice.
Tc3, cytosolic tryparedoxin peroxidase, cruzipain and TS showed the best outcome after infection in survival level and parasitemia. According to these data, these groups were also assessed using the ISCOMATRIX™ adjuvant which is being used in clinical trials.
Taken together, our results showed that the TS overcomes the performance of other antigens when the same model is employed, confirming that TS is a promising antigen that could be used as a vaccine against T. cruzi.